University of Hertfordshire

Flurbinitroxybutylester: a novel anti-inflammatory drug has enhanced antithrombotic activity

Research output: Contribution to journalArticlepeer-review

  • G. Cirino
  • C. Cicala
  • F. Mancuso
  • A. R. Baydoun
  • J. L. Wallace
View graph of relations
Original languageEnglish
Pages (from-to)73-81
JournalThrombosis Research
Publication statusPublished - 1995


We have recently shown that the introduction of a nitroxybutylester moiety into flurbiprofen, to form Flurbi-NO, results in a compound with markedly reduced undesired effects in the gastrointestinal tract. This effect has been shown to be linked to nitric oxide release from the Flurbi-NO. Here we have investigated whether this is associated with a reduction in platelet aggregability in vivo, as assessed in a mouse model of thromboembolism and a rat model of platelet aggregation, and found in both models that Flurbi-NO is more potent than flurbiprofen at inhibiting collagen-induced platelet aggregation. Further in vitro studies using human washed platelets and cells in culture suggest that this is due to the release of NO from Flurbi-NO following the action of (possibly plasma) esterases. Together with our earlier data, these results strongly suggest that Flurbi-NO and other members of this class of drugs, have particular potential as antithrombotic agents devoid of gastrointestinal side effects.


Original article can be found at: Copyright Elsevier Ireland Ltd. DOI: 10.1016/0049-3848(95)00092-6 [Full text of this article is not available in the UHRA]

ID: 122851